Table 5. The relationship between clinicopathological characteristics, ph-STAT1 and ph-STAT3 tumour cell expression and cancer specific survival in patients with high grade necrosis (n=201).

	Univariate analysis		Multivariate analysis
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age (≤50/ >50 years)	1.15(0.68-1.94)	0.604
Size (≤20/ 21-50/ >50 mm)	1.66(1.09-2.50)	0.016		0.330
Grade (I / II / III)	1.17(0.78-1.73)	0.452
Involved lymph node (−ve/+ve)	2.36(1.39-4.03)	0.002		0.156
ER status (no/yes)	0.77(0.48-1.24)	0.303
PR status (no/yes)	0.78(0.49-1.27)	0.326
Her-2 status (no/ yes)	1.19(0.71-2.02)	0.503
Lymphatic vessel invasion (no/yes)	3.28(1.98-5.44)	<0.001	2.53(1.45-4.44)	0.001
Blood vessel invasion (no/yes)	2.78(1.62-4.77)	<0.001	2.03(1.14-3.59)	0.015
CD68+ (low/moderate/high)	0.68(0.51-0.89)	0.007	0.65(0.46-0.91)	0.013
CD4+ (low/moderate/high)	0.78(0.59-1.02)	0.064		0.425
CD8+ (low/moderate/high)	0.51(0.38-0.69)	<0.001	0.65(0.47-0.76)	0.012
CD138+(low/moderate/high)	1.18(0.92-1.52)	0.195
Tumour stroma percentage (low/high)	2.14(1.32-3.47)	0.002		0.197
Tumour budding (low/high)	2.51(1.56-4.04)	<0.001	1.91(1.14-3.19)	0.014
Ph-STAT1 tumour cell expression (low/moderate/high)	0.83(0.63-1.12)	0.230
Ph–STAT3 tumour cell expression (low/moderate/high)	0.65(0.46-0.90)	0.011	0.69(0.51-0.95)	0.030
Locoregional treatment (lumpectomy+radiotherapy/ mastectomy +radiotherapy)	2.37(1.33-4.20)	0.003	2.03(1.19-3.74)	0.024
Systemic treatment (hormonal/hormonal+ chemotherapy/chemotherapy/ none)	1.11(0.86-1.43)	0.415